Cambridge Investment Research Advisors
BMY.RT

Cambridge Investment Research Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,322,759
Closed -$913K – 3033
2020
Q4 		$913K Sell
1,322,759
-60,193
-4% -$128K 0.01% 1371
2020
Q3 		$3.11M Buy
1,382,952
+1,248,713
+930% +$3.57M 0.02% 602
2020
Q2 		$481K Sell
134,239
-152
-0.1% -$548 ﹤0.01% 1577
2020
Q1 		$511K Buy
134,391
+5,248
+4% +$17.3K ﹤0.01% 1354
2019
Q4 		$389K Buy
+129,143
New +$336K ﹤0.01% 1744

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Cambridge Investment Research Advisors's BMY.RT Position: Q1 2021 in Review

Cambridge Investment Research Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,322,759 shares — an estimated $913K sold.

Cambridge Investment Research Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.11M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cambridge Investment Research Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,322,759 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $913K.
  • Cambridge Investment Research Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Cambridge Investment Research Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.11M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2021, filed 7 May 2021.